M-Insightlogo
  • Multiple Myeloma & MRD
    dropmenu
    What is Multiple Myeloma?
    MM is a blood cancer characterized by the clonal expansion of plasma cells in the bone marrow. Myeloma is rare, accounting for 1% of all cancers.
    dropmenu
    MM diagnosis and monitoring
    Multiple myeloma diagnosis and monitoring are based on clinical symptoms and a variety of laboratory tests. M-protein detection and quantification are integral parts of diagnosis and monitoring of MM.
    dropmenu
    What is MRD ?
    MRD stands for Minimal Residual Disease. It refers to the very small number of myeloma cells that are present in the bone marrow after treatment. These remaining cells often cannot be detected through traditional tests of treatment response. However, they have the potential to multiply and cause relapse.
  • M-inSight®
  • Resources
  • About us
    dropmenu
    Corgenix
    Contracted Services to Improve Patient Outcomes
    dropmenu
    Sebia
    The new language of life
  • Contact us
  • How to order?
    • Order M-inSight®
  • Multiple Myeloma & MRD
  • M-inSight®
  • Resources
  • About us
  • Contact us
  • How to order?
  • Order M-inSight®
  • Back
  • What is Multiple Myeloma?
  • MM diagnosis and monitoring
  • What is MRD ?
  • Back
  • Corgenix
  • Sebia

Author: cbernier@sebia.com

February 2026

Clonotypic Peptide MS to monitor M-Protein reduction in Patients with relapsed/refractory MM from IKEMA study – ASH 2025
August 2025

CAP/CLIA Accreditation for Laboratory Services
June 2025

International Myeloma Society – IMS 2025
February 2025

European Myeloma Network Meeting – EMN 2025
February 2025

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with MM – Pharmaceutics 2025
January 2025

Clonotypic Peptide Mass Spectrometry to Define Functional Cure in Patients with Multiple Myeloma Undergoing Maintenance Cessation – ASH 2024
November 2024

American Society of Hematology – ASH 2024
November 2024

MRD tracking in blood using a de novo sequencing from SPEP gel of M-protein in Multiple Myeloma Patients – IMS 2024
November 2024

Urine Bence Jones proteins as a novel source for De Novo light chain sequencing – IMS 2024
August 2024

Advances in minimal residual disease monitoring in multiple myeloma – Clinical Laboratory Sciences 2023
  • 1
  • 2
  • 3
  • 4
  • Suivant
See what others can't
Order M-inSight®

Multiple Myeloma & MRD

Multiple Myeloma MRD Monitoring Diagnosis and Monitoring

M-inSight®

Discover M-inSight® Ordering information Resources Contact us
© 2026 M-inSight®
Terms of Use
Privacy policy
Privacy Practices
Claims presented in the website are supported by references on the Resources page.